Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Promore Pharma’s most important task is to develop new products aiming to improve the quality of life for patients with difficult-to-treat wounds and various types of scarring, primarily following surgery.
Evotec SE announced the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”), for up to $ 90 m including potential performance-based earn-out components expected within the next three years.
Evotec SE announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”) based in Seattle, WA, USA for up to US$ 90 m (approx. EUR 81 m; EUR/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years.
The deal gives Amryt a toehold in the United States with the previously approved Juxtapid, a treatment for the inherited cholesterol disorder homozygous familial hypercholesterolaemia.
Merck is buying all outstanding shares of Peloton, a clinical-stage oncology company, for an upfront payment of $1.05 billion in cash. Peloton will also be eligible for another $1.15 billion based on various regulatory and sales milestones.
Auris Medical Holding Ltd. announced that it has received written notification from the Nasdaq Hearings Panel notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.
Auris Medical Holding Ltd. announced today the closing of its previously announced underwritten public offering
GeoVax Labs, Inc. announced its financial results for the three months ended March 31, 2019 and provided an update on its corporate development progress.
Evotec SE reported financial results and corporate updates for the first quarter of 2019.
Soligenix, Inc. announced its recent accomplishments and financial results for the quarter ended March 31, 2019.